“For Blood and Money” charts a race to develop a blockbuster drug
Nathan Vardi’s book brings to life a contest between two pharmaceutical firms
Few scientific endeavours are more lucrative than developing a blockbuster drug—or a blockbuster vaccine. Lipitor, Pfizer’s cholesterol-lowering medication, is reputed to have made the company more than $160bn. Advair, an asthma drug, has earned tens of billions of dollars for GSK (formerly GlaxoSmithKline). And BioNTech, a firm few people had heard of before the covid-19 pandemic, has made billions from its mRNA vaccine.
This article appeared in the Culture section of the print edition under the headline “Health is wealth”
Culture January 14th 2023
- To their critics, Mexican drug ballads glorify violence
- Cinema meets radicalism in “Picture in the Sand”
- The quest for the perfect chip
- “For Blood and Money” charts a race to develop a blockbuster drug
- How Cambodian music survived the horrors of the Khmers Rouges
- The truth about Stone Mountain’s giant Confederate memorial
From the January 14th 2023 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Culture
Want to spend time with a different American president?
Five presidential biographies to distract you from the news
Los Angeles has lost some of its trailblazing architecture
How will it rebuild?
What firms are for
The framework for thinking about business and capitalism is hopelessly outdated, argues a new book
Greg Gutfeld, America’s most popular late-night host, rules the airwaves
The left gave him his perch
Astrology is booming, thanks to technology and younger enthusiasts
Gen Z is full of stargazing users
Why matcha, made from green tea, is the drink of the moment
Is it really a healthy alternative to coffee? Not the way Gen Z orders it